Nadph-cytochrome p-450 reductase is involved in flunitrazepam reductive metabolism in hep G2 and hep 3b cells

Journal of Toxicology and Environmental Health - Part A

Volumn 67, Issue 2, 2004, Pages 109-124

  Peng, Fu Chuo ^a   Hsin Hui, Chaing ^a   Sheng Hui, Tang ^a   Pei Chun, Chen ^a   Shao Chun, Lu ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINOFLUNITRAZEPAM; CYTOCHROME P450 REDUCTASE; DRUG METABOLITE; FLUNITRAZEPAM; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CELL STRAIN; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME PURIFICATION; HEPATOMA CELL; HUMAN; HUMAN CELL; HYPOXIA; INHIBITION KINETICS; LYMPHOBLAST; MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 1642430598     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287390490264767     Document Type: Article

References (45)

1. Aboagye, E. O., Lewis, A. D., Tracy, M., and Workman, P. 1997. Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR4554). Biochew. Pharmacol. 54:1217-1224.
2. Aden, D. P., Fogel, A, Plotkin, S., Damjanov, I., and Knowles, B. B. 1979. Controlled synthesis of HbsAg in a differentiated human liver carcinoma-derived cell line. Nature 282:615-616.
3. Ahmed, M. K., Casida, J. E., and Nichols, R. E. 1958. Bovine metabolism of organophosphorus insecticides: Significance of rumen fluid with particular reference to parathion. J Agric. Food Chew. 6:740-746.
4. Amrein, R., Cano, J. P., and Hügin, W. 1976. Pharmakokinestische und pharmakodynamische befunde nach einmaliger intravenöser, intramuskulärer und oraler application von Rophypnol. In Bisherige Erfahrungen mit “Rophynol” (Flunitrazepam) in der Anästhesiologie und Intensivtherapir, eds. W. Hügin, G. Hossli, and M. Gemperle, pp. 39-56. Basel: Editiones Roche.
5. Anglin, D., Spear, K. L., and Huston, H. R. 1997. Flunitrazepam and its involvement in date or acquaintance rape. AcadEwerg. Med. 4:323-326.
6. Berthault, F, Kintz, P., and Mangin, P. 1996. Simultaneous high-performance liquid chromatographic analysis of flunitrazepam and four metabolites in serum. J, Chrowatogr. B Biowed. Appl. 685:383-387.
7. Bouma, M. E., Rogier, R., Verthier, N., LaBarre, C., and Feldmann, G., 1989. Further cellular investigation of the human hepatoblastoma-derived cell line, Hep G2, Morphology and immunocytochemical studies of hepatic-secreted proteins. In Vitro Cell. Dev. Biol. 25:267-275.
8. Cahill, A., and White, I. N. H. 1990. Reductive metabolism of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) and the induction of unscheduled DNA synthesis in rat and human derived cell lines. Carcono-genesis 11:1407-1411.
9. Chuo, P., Liou, M. Y., Lai, M. Y., Hsiao, M. L., and Chang, H. J. 1999. Time trend of substance use among adolescent students in Taiwan, 1991-1996. J. Forwosan Med. Assoc. 98:827-831.
10. Coller, J. K., Somogyi, A. A., and Bochner, F. 1998. Quantification of flunitrazepam's oxidative metabolites, 3-hydroxyflunitrazepam and demethylflunitrazepam, in hepatic microsomal incubations by highperformance liquid chromatography. J. Chrowatogr. B 719:87-92.
11. Coller, J. K., Somogyi, A. A., and Bochner, F. 1999. Flunitrazepam oxidative metabolism in human microsomes: Involvement of CYP2C19 and CYP3A4. Xenobiotica 29:973-986.
12. Dawson, J. R., Adams, D. J., and Wolf, C. R. 1985. Induction of drug metabolizing enzymes in human liver cell line Hep G2. FEBS Lett. 183:219-222.
13. Dearfield, K. L., Jacobson-Kram, D., Buenaventura, S. K., and Williams, J. R. 1983. In vitro assays of in vivo exposure to cyclophosphamide: Induction of sister chromatic exchanges in peripheral lymphocytes, bone marrow cells and in cultured cells exposed to plasma. Mutat. Res. 158:97-104.
14. Deinl, I., Mahr, G., and Meyer, L. V. 1998. Determination of flunitrazepam and its main metabolites in serum and urine by HPLC after mixed-mode solid-phase extraction. J. Anal. Toxicol. 22:197-202.
15. Diamond, L., Kruszewski, F., Aden, D. P., Knowles, B. B., and Baird, W. M. 1985. Metabolic activation to benzo(a)pyrene by a human hepatoma cell line. Carcinogenesis 1:871-875.
16. Duthie, S. J., and Grant, M. H. 1989. The toxicity of menadione and mitozantrone in human liver-derived Hep G2 hepatoma cells. Biochem. Pharmacol. 79:249-256.
17. Duthie, S. J., Coleman, C. S., and Grant, M. H. 1988. Status of reduced glutathione in the human hepatoma cell line Hep G2. Biochem. Pharmacol. 46:629-635.
18. Duthie, S. J., Melvin, W. T., and Burke, M. D. 1994. Bromobenzene detoxification in the human liver-derived Hep G2 hepatoma cell line. Xenobiotica 24:265-279.
19. Farre, M., Teran, M. T., Roset, P. N., Mas, M., Torrens, M., and Cami, J. 1998. Abuse liability of flunitrazepam among methadone maintained patients. Psychopharmacology (Berl.) 140:486-495.
20. Grant, M. H., Doostdar, H., Maley, M., Melvin, W. T., Engeset, J., and Burke, M. D. 1988a. Glucuronida-tion in rat and human hepatocyte cultures and in human Hep G2 hepatoma cells. In Cellular and molecular aspects of glucuronidation, eds. G. Siest, J. Magdalu, and B. Birchall, vol. 173, pp. 129-136. Collogue INSERM/John Libbey Eurotext.
21. Grant, M. H., Duthie, S. J., Gray, A. G., and Burke, M. D. 1988b. Mixed function oxidase and UDP-glucuronyltransferase activities in the human Hep G2 hepatoma cell line. Biochem. Pharmacol. 37:4111-4116.
22. Guengerich, F. P., Wang, P., and Davidson, N. K. 1982. Estimation of isoenzymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate electrophoresis. Biochemistry 21:1698-1706.
23. Hall, T. J., James, P. R., and Cambridge, G. 1993. Development of an in vitro hepatoxicity assay for assessing effects of chronic drug exposure. Res. Commun. Chem. Pathol. Pharmacol. 79:249-256.
24. Herwick, D. S. 1980. Reduction metabolism of nitrogen-containing functional group. In Metabolic basis of detoxification, eds. W. B. Jakoby, J. R. Bend, and J. Caldwell, pp. 151-170. New York: Academic Press.
25. Hesse, L. M., Venkatakrishnan, K., Von Moltke, L. L., Shader, R. I., and Greenblatt, D. J. 2001. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab. Dispos. 29:133-140.
26. Hodgson, E., Sliver, I. S., Butler, L. E., Lawton, M. P., and Levi, P. E. 1991. Metabolism. In Handbook of pesticide toxicology: General principles, eds. W. J. Hayes, Jr., and E. R. Laws, Jr., vol. 1, pp. 107-167. San Diego: Academic Press.
27. Kilicarslan, T., Haning, R. L., Rettie, A. E., Busto, U., Tyndale, R. F., and Sellers, E. M. 2001. Flunitrazepam metabolism by cytochrome P450s 2C19 and 3A4. Drug Metab. Dispos. 29:460-465.
28. Knowles, B. B., Howe, C. C., and Aden, D. P. 1980. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209:497-499.
29. Korttila, M. A., and Linnoila, M. 1976. Amnesic action of and skills related driving after intravenous flunitrazepam. Acta Anaesthesiol. Scand. 20:160-168.
30. 4. Nature 227:680-685.
31. Limbosch, S. J. 1983. Benzo[a]pyrene and aldrin metabolizing activation in human and rat hepatoma cell lines. NCIMonogr. 71:281-286.
32. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. 1951. Protein determinations with Folin phenol reagent. J. Biol. Chem. 193:265-275.
33. Masuda, Y., and Ozaki, M. 1993. Reduction of nitro and azo compounds by NADPH-cytochrome P-450 reductase-cytochrome c heme peptide system. Biol. Pharm. Bull. 16:112-115.
34. Mattila, M. A., and Lami, H. M. 1980. Flunitrazepam: A review of its pharmacological properties and therapeutic use. Drugs 20:353-374.
35. Melo, T., Ballinger, J. R., and Rauth, A. M. 2000. Role of NADPH:cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging tumor hypoxia. Biochem. Pharmacol. 60:625-634.
36. Phillips, A. H., and Langdon, R. G. 1962. Hepatic triphosphopyridine nucleotide-cytochrome c reductase isolation, characterization and kinetic studies. J. Biol. Chem. 237:2652-2660.
37. Rickert, V. I., and Wiemann, C. M. 1998. Date rape among adolescents and young adults. Pediatr. Adolesc. Gynecol. 11:167-175.
38. Sassa, S., Sugita, O., Galbraith, R. A., and Kappas, A. 1987. Drug metabolism by the human hepatoma cell, Hep G2. Biochem. Biophys. Res. Commun. 143:52-57.
39. Saum, C. A., and Inciardi, J. A. 1997. Rohynol misuse in the United States. Subst. Use Misuse 32:723-731.
40. Simmons, M. M., and Cupp, M. J. 1998. Use and abuse of flunitrazepam. Ann. Pharmacother. 32:117-119.
41. Skehan, P., Storeng, R., Scudiero, D., Monks, A., Mcmahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. JNCI 82:107-112.
42. Slepneva, I. A., Sergeeva, A. V., and Khramtsov, V. V. 1995. Reversible inhibition of NADPH-cytochrome P450 reductase by alpha-lipoic acid. Biochem. Biophys. Res. Commun. 214:1246-1253.
43. Towbin, H., Staehelin, T., and Gordon, J. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc. Nat. Acad. Sci. USA 76:4350-4354.
44. Williams, C. H., and Kamin, H. 1962. Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver. J Biol. Chem. 237:587-595.
45. Woods, J. H., and Winger, G. 1997. Abuse liability of flunitrazepam. J. Clin. Psychopharmacol. 17: 1S-57S.